EcoDrugPlus

Motilin Receptor

Ensembl ID : ENSCSEG00000007241
Gene Symbol: MLNR
3 Cross references
172 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSCSEG00000006028
Gene Symbol: LOC103380168
2 Cross references
186 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSCSEG00000000201
Gene Symbol: LOC103392924
3 Cross references
195 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSCSEG00000018368
Gene Symbol: NPR1
3 Cross references
194 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSCSEG00000015407
Gene Symbol: NPR1
3 Cross references
186 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSCSEG00000000622
Gene Symbol: NPR2
1 Cross references
191 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSCSEG00000006898
Gene Symbol: LOC103397899
3 Cross references
199 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSCSEG00000001351
Gene Symbol: LOC103390439
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSCSEG00000020458
Gene Symbol: LOC103392505
3 Cross references
192 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSCSEG00000002593
Gene Symbol: LOC103383510
4 Cross references
201 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSCSEG00000002311
Gene Symbol: LOC103384655
3 Cross references
195 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSCSEG00000009046
Gene Symbol: LOC103398445
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).